CAJ | 학술논문

目的：观察恩度联合吉西他滨治疗晚期肝细胞癌的近期疗效和安全性。方法57例晚期肝细胞癌患者随机分为2组，治疗组29例给予恩度联合吉西他滨治疗，对照组28例仅给予吉西他滨治疗，2组患者均至少接受2周期的化疗，然后评价近期疗效和毒副反应。结果治疗组有效率为51.7%，高于对照组的25.0%（P<0.05）；临床获益率为82.8%，高于对照组的57.1%（P<0.05）；中位肿瘤进展时间分别为6.5个月和3.5个月（P<0.05）。2组患者治疗后生活质量评分均有所提高，以治疗组提高更明显（P<0.05）。2组患者治疗后血清AFP、CA19-9水平均有不同程度下降，以治疗组下降较为明显（ P<0.05）。2组患者治疗后中、重度毒副反应发生率相近（P>0.05）。结论恩度联合吉西他滨治疗晚期肝细胞癌安全有效，值得临床推广应用。
목적：관찰은도연합길서타빈치료만기간세포암적근기료효화안전성。방법57례만기간세포암환자수궤분위2조，치료조29례급여은도연합길서타빈치료，대조조28례부급여길서타빈치료，2조환자균지소접수2주기적화료，연후평개근기료효화독부반응。결과치료조유효솔위51.7%，고우대조조적25.0%（P<0.05）；림상획익솔위82.8%，고우대조조적57.1%（P<0.05）；중위종류진전시간분별위6.5개월화3.5개월（P<0.05）。2조환자치료후생활질량평분균유소제고，이치료조제고경명현（P<0.05）。2조환자치료후혈청AFP、CA19-9수평균유불동정도하강，이치료조하강교위명현（ P<0.05）。2조환자치료후중、중도독부반응발생솔상근（P>0.05）。결론은도연합길서타빈치료만기간세포암안전유효，치득림상추엄응용。
Objective Toinvestigatetheshort-termeffectsandsafetyofendostarcombinedwithgemcitabinein thetreatmentofadvancedhepatocellularcarcinoma.Methods Fifty-sevenpatientswithadvancedhepatocellular carcinoma were randomly divided into two groups,29 patients of the treatment group received endostar plus gemcit-abine,and 28 patients of the control group received gemcitabine only. All the patients received at least 2 cycles of chemotherapy,andtheshort-termeffectsandtoxicitieswereobserved.Results Theresponseratewas51.7%in the treatment group,and was 25. 0% in the control group(P<0. 05). The clinical benefit rate was 82. 8% in the treatment group,and was 57. 1% in the control group(P<0. 05). The median tumor to progression time was 6. 5 months in the treatment group,and was 3. 5 months in the control group(P<0. 05). The scores of quality of life in the two groups were both increased,and the increasing rate in the treatment group was significantly higher than that in the control group(P<0. 05). The serum levels of AFP and CA19-9 in the two groups were decreased significant-ly after the treatment,and the decreasing degree in treatment group was higher than that in the control group( P<0. 05). There were no significant statistical differences in the incidence of moderate-severe toxicities between the twogroups.Conclusion Endostarcombinedwithgemcitabineiseffeetiveandsafeinthetreatmentofadvanced hepatocellular carcinoma.